Negativ
●
Proactive Investors
●
vor 5 Monaten
Deutsche Bank has cut its price target for Novo Nordisk (NYSE:NVO) by 16% to DKK400 following a turbulent week for the Danish pharmaceutical group, citing revenue headwinds, management uncertainty and clinical trial risks. Emmanuel Papadakis, equity analyst at Deutsche Bank, described the period post fourth-quarter results as “the best of times, the worst of times”, reflecting a mix of strong p...